| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| 31 |
- glp-1 비만
- GLP-1 치료제
- 제약바이오
- tern-601
- survodutide
- Pfizer
- GLP-1
- Novo Nordisk
- VK2735
- Mash
- danuglipron
- CAR-T
- VKTX
- gsbr-1290
- orforglipron
- 경구용 glp-1
- GPCR
- pemvidutide
- lilly
- tirzepatide
- il-17 inhibitor
- GLP-1/GIP
- glp-1 비만치료제
- Viking Therapeutics
- 노보노디스크
- Nash
- nash/mash
- Semaglutide
- 비만치료제
- 바이오스터디
- Today
- Total
목록2024 ASCO (2)
제약바이오 츄롸이츄롸이
Caribou Biosciences - 2024 ASCO update (2024-06-02)
https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-presents-encouraging-clinical-data-cb-010 Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous ..
Blackdiamond Therapeutics (NASDAQ: BDTX) - 2024 ASCO?
NOVEMBER 7, 2023 Abstract Submission Opens FEBRUARY 6, 2024 at 11:59 PM ET Abstract Submission Deadline MARCH 11, 2024 at 12:00 PM ET Late-breaking Submission Deadline (Abstract placeholder is required by the February 6 deadline) MARCH 29, 2024 Abstract Notifications Sent to First Authors APRIL 7, 2024 at 11:59 PM ET Abstract Withdrawal Deadline APRIL 24, 2024 at 10:00 AM ET Abstract Titles, inc..